Cargando…
Cell proliferation inhibitors and apoptosis promoters
Cancer is characterised by uncontrolled proliferation and prolonged cell survival. In some cases, tumour formation is the result from aberrant activity of various cell-cycle regulators leading to chromosome instability or from alteration of the apoptosis pathway. Ovarian cancer is an entity in which...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573461/ https://www.ncbi.nlm.nih.gov/pubmed/33240445 http://dx.doi.org/10.1016/j.ejcsup.2019.09.002 |
_version_ | 1783597444659937280 |
---|---|
author | Perez-Fidalgo, J. Alejandro |
author_facet | Perez-Fidalgo, J. Alejandro |
author_sort | Perez-Fidalgo, J. Alejandro |
collection | PubMed |
description | Cancer is characterised by uncontrolled proliferation and prolonged cell survival. In some cases, tumour formation is the result from aberrant activity of various cell-cycle regulators leading to chromosome instability or from alteration of the apoptosis pathway. Ovarian cancer is an entity in which cell-cycle alterations are common. P53, a key regulator of checkpoint G1, is frequently altered in high-grade serous ovarian cancer. Targeting cell-cycle regulators will lead to mitotic catastrophe and cell death in these tumours. Promoting apoptosis is another target that is gaining interest in ovarian cancer. In this review, the most relevant evidence of clinical studies in ovarian cancer with compounds targeting cell cycle or promoting apoptosis is summarised. |
format | Online Article Text |
id | pubmed-7573461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-75734612020-11-24 Cell proliferation inhibitors and apoptosis promoters Perez-Fidalgo, J. Alejandro EJC Suppl Article Cancer is characterised by uncontrolled proliferation and prolonged cell survival. In some cases, tumour formation is the result from aberrant activity of various cell-cycle regulators leading to chromosome instability or from alteration of the apoptosis pathway. Ovarian cancer is an entity in which cell-cycle alterations are common. P53, a key regulator of checkpoint G1, is frequently altered in high-grade serous ovarian cancer. Targeting cell-cycle regulators will lead to mitotic catastrophe and cell death in these tumours. Promoting apoptosis is another target that is gaining interest in ovarian cancer. In this review, the most relevant evidence of clinical studies in ovarian cancer with compounds targeting cell cycle or promoting apoptosis is summarised. Elsevier 2020-08-22 /pmc/articles/PMC7573461/ /pubmed/33240445 http://dx.doi.org/10.1016/j.ejcsup.2019.09.002 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Perez-Fidalgo, J. Alejandro Cell proliferation inhibitors and apoptosis promoters |
title | Cell proliferation inhibitors and apoptosis promoters |
title_full | Cell proliferation inhibitors and apoptosis promoters |
title_fullStr | Cell proliferation inhibitors and apoptosis promoters |
title_full_unstemmed | Cell proliferation inhibitors and apoptosis promoters |
title_short | Cell proliferation inhibitors and apoptosis promoters |
title_sort | cell proliferation inhibitors and apoptosis promoters |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573461/ https://www.ncbi.nlm.nih.gov/pubmed/33240445 http://dx.doi.org/10.1016/j.ejcsup.2019.09.002 |
work_keys_str_mv | AT perezfidalgojalejandro cellproliferationinhibitorsandapoptosispromoters |